The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication
Promotes Collagen and Extracellular Matrix Production GHK-Cu isnt just about hair
The injectable has the longer track record - HealthiCare has written 15,000+ GLP-1 prescriptions, and the injectable form is the most common starting point
Non-alcoholic fatty liver disease (NAFLD) often improves substantially with Retatrutide treatment, as the combination of weight loss and direct metabolic effects targets hepatic fat stores
I think the story of 2026 will involve food manufacturers attempting to fill that gap by capturing a GLP-1 premium through higher-margin product offerings, he said